Premium
Dominant high expression of wild‐type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole‐section immunohistochemical analysis
Author(s) -
Oh Hyeon Jeong,
Kim Jung Ho,
Lee Tae Hun,
Park Hye Eun,
Bae Jeong Mo,
Lee Hye Seung,
Kang Gyeong Hoon
Publication year - 2017
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12770
Subject(s) - microsatellite instability , immunohistochemistry , colorectal cancer , oncology , medicine , heat shock protein , biomarker , tumor infiltrating lymphocytes , biology , cancer , pathology , immunotherapy , cancer research , microsatellite , gene , allele , biochemistry
The aim of this study is to establish heat shock protein 110 ( HSP 110) as a prognostic biomarker of colorectal carcinomas ( CRC s) with microsatellite instability‐high ( MSI ‐H) by considering the intratumoral heterogeneity of HSP 110 expression. We performed whole‐section immunohistochemistry ( IHC ) for wild‐type HSP 110 ( HSP 110wt) in 164 MSI ‐H CRC s. The intensity of the HSP 110wt expression in tumor cells was semiquantitatively scored (0/1/2/3), and the HSP 110wt expression status of each tumor was classified as low or high using the following four scoring criteria: H‐score, dominant intensity score, lowest intensity score, and highest intensity score. Among the four criteria, only the dominant intensity score‐based dichotomous classification of HSP 110wt expression was significantly associated with a difference in disease‐free survival (log‐rank p = 0.035) in 164 MSI ‐H CRC s. The HSP 110wt‐low MSI ‐H CRC s were significantly correlated with larger deletions in the HSP 110 T 17 mononucleotide repeat (≥4 bp; p < 0.001). In conclusion, the dominant intensity score‐based assessment of HSP 110wt IHC can be a simple and useful method for the prognostic stratification of MSI ‐H CRC s. It is expected that HSP 110wt IHC may be used to identify a subgroup of MSI ‐H CRC s with poor prognosis and/or candidates for further treatment, such as immunotherapy using immune checkpoint inhibitors in MSI ‐H CRC s.